Brussels (Belgium), 19 June 2024

IPOPI welcomes newly elected European Parliament

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) warmly

welcomes the elected Members of the European Parliament (MEPs) for their appointment

following the European elections. We also would like to express our deepest gratitude to the

long-standing MEP supporters that did not renew their mandates for this parliamentary term,

for their commitment and passion in supporting the voice of patients with primary

immunodeficiencies in the European Union.

As the global organisation representing patients with primary immunodeficiencies (PIDs) we

look forward to collaborating with the new Parliament to ensure that patients with rare and

chronic disorders and health in general remain a priority in the new political agenda of the

European Parliament.

IPOPI launched a political manifesto following its last PID Forum on "Empowering the PID

community through rare disease policies 2024-2029" in March 2024. In this manifesto, IPOPI

calls on the European Union's (EU) policymakers to take steps to accelerate early diagnosis

(including newborn screening), patient access to safe and affordable medicinal products,

innovative treatments and accessible care, including cross-border treatment when needed,

as well as investment in research in the area of health. Increasing awareness and funding

for rare diseases can also support a more holistic approach to the non-medical needs of PID

1



patients and improve quality of life and outcomes.

IPOPI will continue to work with the elected MEPs and the long-time MEP supporters to continue making a difference for persons with primary immunodeficiencies and their families, on the basis of the priorities set by the Manifesto, so as to ensure that all persons can have access to the highest level of health and well-being, no matter how rare their disease is.

Martine Pergent

IPOPI President

Johan Prevot

IPOPI Executive Director